meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   
insufficient data

Interactive explorer of NMA results

baricitinib vs. casirivimab/imdevimab (Ronapreve) 0.89 [0.58; 1.36]0.89 [0.58;1.36]baricitinib vs. casirivimab/imdevimab (Ronapreve) 0.89 [0.58; 1.36]baricitinib vs. control baricitinib better 0.64 [0.50; 0.82]0.64 [0.50;0.82]baricitinib vs. control baricitinib better 0.64 [0.50; 0.82]baricitinib vs. convalescent plasma treatment baricitinib better 0.73 [0.54; 0.98]0.73 [0.54;0.98]baricitinib vs. convalescent plasma treatment baricitinib better 0.73 [0.54; 0.98]baricitinib vs. corticosteroids baricitinib better 0.72 [0.54; 0.97]0.72 [0.54;0.97]baricitinib vs. corticosteroids baricitinib better 0.72 [0.54; 0.97]baricitinib vs. interferon 0.78 [0.52; 1.17]0.78 [0.52;1.17]baricitinib vs. interferon 0.78 [0.52; 1.17]baricitinib vs. remdesivir 0.78 [0.52; 1.16]0.78 [0.52;1.16]baricitinib vs. remdesivir 0.78 [0.52; 1.16]baricitinib vs. sarilumab 0.92 [0.54; 1.55]0.92 [0.54;1.55]baricitinib vs. sarilumab 0.92 [0.54; 1.55]baricitinib vs. tocilizumab 0.83 [0.62; 1.10]0.83 [0.62;1.10]baricitinib vs. tocilizumab 0.83 [0.62; 1.10]baricitinib vs. tofacitinib 1.22 [0.36; 4.18]1.22 [0.36;4.18]baricitinib vs. tofacitinib 1.22 [0.36; 4.18]casirivimab/imdevimab (Ronapreve) vs. baricitinib 1.13 [0.74; 1.72]1.13 [0.74;1.72]casirivimab/imdevimab (Ronapreve) vs. baricitinib 1.13 [0.74; 1.72]casirivimab/imdevimab (Ronapreve) vs. control 0.72 [0.51; 1.01]0.72 [0.51;1.01]casirivimab/imdevimab (Ronapreve) vs. control 0.72 [0.51; 1.01]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment 0.82 [0.56; 1.19]0.82 [0.56;1.19]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment 0.82 [0.56; 1.19]casirivimab/imdevimab (Ronapreve) vs. corticosteroids 0.82 [0.56; 1.19]0.82 [0.56;1.19]casirivimab/imdevimab (Ronapreve) vs. corticosteroids 0.82 [0.56; 1.19]casirivimab/imdevimab (Ronapreve) vs. interferon 0.88 [0.55; 1.40]0.88 [0.55;1.40]casirivimab/imdevimab (Ronapreve) vs. interferon 0.88 [0.55; 1.40]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.88 [0.55; 1.39]0.88 [0.55;1.39]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.88 [0.55; 1.39]casirivimab/imdevimab (Ronapreve) vs. sarilumab 1.03 [0.58; 1.84]1.03 [0.58;1.84]casirivimab/imdevimab (Ronapreve) vs. sarilumab 1.03 [0.58; 1.84]casirivimab/imdevimab (Ronapreve) vs. tocilizumab 0.93 [0.64; 1.35]0.93 [0.64;1.35]casirivimab/imdevimab (Ronapreve) vs. tocilizumab 0.93 [0.64; 1.35]casirivimab/imdevimab (Ronapreve) vs. tofacitinib 1.38 [0.39; 4.81]1.38 [0.39;4.81]casirivimab/imdevimab (Ronapreve) vs. tofacitinib 1.38 [0.39; 4.81]control vs. baricitinib baricitinib better 1.56 [1.21; 2.01]1.56 [1.21;2.01]control vs. baricitinib baricitinib better 1.56 [1.21; 2.01]control vs. casirivimab/imdevimab (Ronapreve) 1.39 [0.99; 1.96]1.39 [0.99;1.96]control vs. casirivimab/imdevimab (Ronapreve) 1.39 [0.99; 1.96]control vs. convalescent plasma treatment 1.14 [0.98; 1.33]1.14 [0.98;1.33]control vs. convalescent plasma treatment 1.14 [0.98; 1.33]control vs. corticosteroids 1.13 [0.97; 1.32]1.13 [0.97;1.32]control vs. corticosteroids 1.13 [0.97; 1.32]control vs. interferon 1.22 [0.89; 1.68]1.22 [0.89;1.68]control vs. interferon 1.22 [0.89; 1.68]control vs. remdesivir 1.22 [0.90; 1.66]1.22 [0.90;1.66]control vs. remdesivir 1.22 [0.90; 1.66]control vs. sarilumab 1.43 [0.90; 2.28]1.43 [0.90;2.28]control vs. sarilumab 1.43 [0.90; 2.28]control vs. tocilizumab tocilizumab better 1.29 [1.13; 1.48]1.29 [1.13;1.48]control vs. tocilizumab tocilizumab better 1.29 [1.13; 1.48]control vs. tofacitinib 1.91 [0.57; 6.36]1.91 [0.57;6.36]control vs. tofacitinib 1.91 [0.57; 6.36]convalescent plasma treatment vs. baricitinib baricitinib better 1.37 [1.02; 1.85]1.37 [1.02;1.85]convalescent plasma treatment vs. baricitinib baricitinib better 1.37 [1.02; 1.85]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) 1.22 [0.84; 1.77]1.22 [0.84;1.77]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) 1.22 [0.84; 1.77]convalescent plasma treatment vs. control 0.88 [0.75; 1.02]0.88 [0.75;1.02]convalescent plasma treatment vs. control 0.88 [0.75; 1.02]convalescent plasma treatment vs. corticosteroids 1.00 [0.80; 1.23]1.00 [0.80;1.23]convalescent plasma treatment vs. corticosteroids 1.00 [0.80; 1.23]convalescent plasma treatment vs. interferon 1.07 [0.76; 1.53]1.07 [0.76;1.53]convalescent plasma treatment vs. interferon 1.07 [0.76; 1.53]convalescent plasma treatment vs. remdesivir 1.07 [0.76; 1.51]1.07 [0.76;1.51]convalescent plasma treatment vs. remdesivir 1.07 [0.76; 1.51]convalescent plasma treatment vs. sarilumab 1.26 [0.77; 2.05]1.26 [0.77;2.05]convalescent plasma treatment vs. sarilumab 1.26 [0.77; 2.05]convalescent plasma treatment vs. tocilizumab 1.14 [0.92; 1.39]1.14 [0.92;1.39]convalescent plasma treatment vs. tocilizumab 1.14 [0.92; 1.39]convalescent plasma treatment vs. tofacitinib 1.68 [0.50; 5.65]1.68 [0.50;5.65]convalescent plasma treatment vs. tofacitinib 1.68 [0.50; 5.65]corticosteroids vs. baricitinib baricitinib better 1.38 [1.03; 1.85]1.38 [1.03;1.85]corticosteroids vs. baricitinib baricitinib better 1.38 [1.03; 1.85]corticosteroids vs. casirivimab/imdevimab (Ronapreve) 1.23 [0.84; 1.78]1.23 [0.84;1.78]corticosteroids vs. casirivimab/imdevimab (Ronapreve) 1.23 [0.84; 1.78]corticosteroids vs. control 0.88 [0.76; 1.03]0.88 [0.76;1.03]corticosteroids vs. control 0.88 [0.76; 1.03]corticosteroids vs. convalescent plasma treatment 1.00 [0.81; 1.24]1.00 [0.81;1.24]corticosteroids vs. convalescent plasma treatment 1.00 [0.81; 1.24]corticosteroids vs. interferon 1.08 [0.76; 1.53]1.08 [0.76;1.53]corticosteroids vs. interferon 1.08 [0.76; 1.53]corticosteroids vs. remdesivir 1.08 [0.76; 1.51]1.08 [0.76;1.51]corticosteroids vs. remdesivir 1.08 [0.76; 1.51]corticosteroids vs. sarilumab 1.27 [0.78; 2.06]1.27 [0.78;2.06]corticosteroids vs. sarilumab 1.27 [0.78; 2.06]corticosteroids vs. tocilizumab 1.14 [0.94; 1.39]1.14 [0.94;1.39]corticosteroids vs. tocilizumab 1.14 [0.94; 1.39]corticosteroids vs. tofacitinib 1.69 [0.50; 5.67]1.69 [0.50;5.67]corticosteroids vs. tofacitinib 1.69 [0.50; 5.67]interferon vs. baricitinib 1.28 [0.85; 1.92]1.28 [0.85;1.92]interferon vs. baricitinib 1.28 [0.85; 1.92]interferon vs. casirivimab/imdevimab (Ronapreve) 1.14 [0.71; 1.81]1.14 [0.71;1.81]interferon vs. casirivimab/imdevimab (Ronapreve) 1.14 [0.71; 1.81]interferon vs. control 0.82 [0.60; 1.12]0.82 [0.60;1.12]interferon vs. control 0.82 [0.60; 1.12]interferon vs. convalescent plasma treatment 0.93 [0.65; 1.32]0.93 [0.65;1.32]interferon vs. convalescent plasma treatment 0.93 [0.65; 1.32]interferon vs. corticosteroids 0.93 [0.65; 1.32]0.93 [0.65;1.32]interferon vs. corticosteroids 0.93 [0.65; 1.32]interferon vs. remdesivir 1.00 [0.64; 1.55]1.00 [0.64;1.55]interferon vs. remdesivir 1.00 [0.64; 1.55]interferon vs. sarilumab 1.17 [0.67; 2.06]1.17 [0.67;2.06]interferon vs. sarilumab 1.17 [0.67; 2.06]interferon vs. tocilizumab 1.06 [0.75; 1.49]1.06 [0.75;1.49]interferon vs. tocilizumab 1.06 [0.75; 1.49]interferon vs. tofacitinib 1.56 [0.45; 5.42]1.56 [0.45;5.42]interferon vs. tofacitinib 1.56 [0.45; 5.42]remdesivir vs. baricitinib 1.28 [0.86; 1.91]1.28 [0.86;1.91]remdesivir vs. baricitinib 1.28 [0.86; 1.91]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.14 [0.72; 1.81]1.14 [0.72;1.81]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.14 [0.72; 1.81]remdesivir vs. control 0.82 [0.60; 1.12]0.82 [0.60;1.12]remdesivir vs. control 0.82 [0.60; 1.12]remdesivir vs. convalescent plasma treatment 0.93 [0.66; 1.32]0.93 [0.66;1.32]remdesivir vs. convalescent plasma treatment 0.93 [0.66; 1.32]remdesivir vs. corticosteroids 0.93 [0.66; 1.31]0.93 [0.66;1.31]remdesivir vs. corticosteroids 0.93 [0.66; 1.31]remdesivir vs. interferon 1.00 [0.65; 1.56]1.00 [0.65;1.56]remdesivir vs. interferon 1.00 [0.65; 1.56]remdesivir vs. sarilumab 1.18 [0.68; 2.05]1.18 [0.68;2.05]remdesivir vs. sarilumab 1.18 [0.68; 2.05]remdesivir vs. tocilizumab 1.06 [0.76; 1.49]1.06 [0.76;1.49]remdesivir vs. tocilizumab 1.06 [0.76; 1.49]remdesivir vs. tofacitinib 1.57 [0.45; 5.43]1.57 [0.45;5.43]remdesivir vs. tofacitinib 1.57 [0.45; 5.43]sarilumab vs. baricitinib 1.09 [0.64; 1.85]1.09 [0.64;1.85]sarilumab vs. baricitinib 1.09 [0.64; 1.85]sarilumab vs. casirivimab/imdevimab (Ronapreve) 0.97 [0.54; 1.72]0.97 [0.54;1.72]sarilumab vs. casirivimab/imdevimab (Ronapreve) 0.97 [0.54; 1.72]sarilumab vs. control 0.70 [0.44; 1.11]0.70 [0.44;1.11]sarilumab vs. control 0.70 [0.44; 1.11]sarilumab vs. convalescent plasma treatment 0.79 [0.49; 1.29]0.79 [0.49;1.29]sarilumab vs. convalescent plasma treatment 0.79 [0.49; 1.29]sarilumab vs. corticosteroids 0.79 [0.49; 1.28]0.79 [0.49;1.28]sarilumab vs. corticosteroids 0.79 [0.49; 1.28]sarilumab vs. interferon 0.85 [0.49; 1.49]0.85 [0.49;1.49]sarilumab vs. interferon 0.85 [0.49; 1.49]sarilumab vs. remdesivir 0.85 [0.49; 1.48]0.85 [0.49;1.48]sarilumab vs. remdesivir 0.85 [0.49; 1.48]sarilumab vs. tocilizumab 0.90 [0.56; 1.46]0.90 [0.56;1.46]sarilumab vs. tocilizumab 0.90 [0.56; 1.46]sarilumab vs. tofacitinib 1.33 [0.37; 4.83]1.33 [0.37;4.83]sarilumab vs. tofacitinib 1.33 [0.37; 4.83]tocilizumab vs. baricitinib 1.21 [0.91; 1.61]1.21 [0.91;1.61]tocilizumab vs. baricitinib 1.21 [0.91; 1.61]tocilizumab vs. casirivimab/imdevimab (Ronapreve) 1.07 [0.74; 1.55]1.07 [0.74;1.55]tocilizumab vs. casirivimab/imdevimab (Ronapreve) 1.07 [0.74; 1.55]tocilizumab vs. control tocilizumab better 0.77 [0.67; 0.89]0.77 [0.67;0.89]tocilizumab vs. control tocilizumab better 0.77 [0.67; 0.89]tocilizumab vs. convalescent plasma treatment 0.88 [0.72; 1.08]0.88 [0.72;1.08]tocilizumab vs. convalescent plasma treatment 0.88 [0.72; 1.08]tocilizumab vs. corticosteroids 0.88 [0.72; 1.07]0.88 [0.72;1.07]tocilizumab vs. corticosteroids 0.88 [0.72; 1.07]tocilizumab vs. interferon 0.95 [0.67; 1.34]0.95 [0.67;1.34]tocilizumab vs. interferon 0.95 [0.67; 1.34]tocilizumab vs. remdesivir 0.94 [0.67; 1.32]0.94 [0.67;1.32]tocilizumab vs. remdesivir 0.94 [0.67; 1.32]tocilizumab vs. sarilumab 1.11 [0.69; 1.80]1.11 [0.69;1.80]tocilizumab vs. sarilumab 1.11 [0.69; 1.80]tocilizumab vs. tofacitinib 1.48 [0.44; 4.96]1.48 [0.44;4.96]tocilizumab vs. tofacitinib 1.48 [0.44; 4.96]tofacitinib vs. baricitinib 0.82 [0.24; 2.80]0.82 [0.24;2.80]tofacitinib vs. baricitinib 0.82 [0.24; 2.80]tofacitinib vs. casirivimab/imdevimab (Ronapreve) 0.73 [0.21; 2.54]0.73 [0.21;2.54]tofacitinib vs. casirivimab/imdevimab (Ronapreve) 0.73 [0.21; 2.54]tofacitinib vs. control 0.52 [0.16; 1.74]0.52 [0.16;1.74]tofacitinib vs. control 0.52 [0.16; 1.74]tofacitinib vs. convalescent plasma treatment 0.60 [0.18; 2.00]0.60 [0.18;2.00]tofacitinib vs. convalescent plasma treatment 0.60 [0.18; 2.00]tofacitinib vs. corticosteroids 0.59 [0.18; 1.99]0.59 [0.18;1.99]tofacitinib vs. corticosteroids 0.59 [0.18; 1.99]tofacitinib vs. interferon 0.64 [0.18; 2.22]0.64 [0.18;2.22]tofacitinib vs. interferon 0.64 [0.18; 2.22]tofacitinib vs. remdesivir 0.64 [0.18; 2.21]0.64 [0.18;2.21]tofacitinib vs. remdesivir 0.64 [0.18; 2.21]tofacitinib vs. sarilumab 0.75 [0.21; 2.72]0.75 [0.21;2.72]tofacitinib vs. sarilumab 0.75 [0.21; 2.72]tofacitinib vs. tocilizumab 0.68 [0.20; 2.27]0.68 [0.20;2.27]tofacitinib vs. tocilizumab 0.68 [0.20; 2.27]Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcorticosteroidsRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNremdesivirRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNconvalescent plasma treatmentRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNbaricitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtofacitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcasirivimab/imdevimab (Ronapreve)Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNinterferonRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtocilizumab Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNsarilumabRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcontroldirect evidencenetwork meta-analysis ROB:highsome concernslowNA

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirconvalescent plasma treatmentbaricitinibtofacitinibcasirivimab/imdevimab (Ronapreve)interferontocilizumab sarilumabcontrol
corticosteroids---1.08
0.76; 1.51		1.00
0.81; 1.24		1.38
1.03; 1.85		1.69
0.50; 5.67		1.23
0.84; 1.78		1.08
0.76; 1.53		1.14
0.94; 1.39		1.27
0.78; 2.06		0.88
0.76; 1.03
remdesivir0.93
0.66; 1.31		---0.93
0.66; 1.32		1.28
0.86; 1.91		1.57
0.45; 5.43		1.14
0.72; 1.81		1.00
0.65; 1.56		1.06
0.76; 1.49		1.18
0.68; 2.05		0.82
0.60; 1.12
convalescent plasma treatment1.00
0.80; 1.23		1.07
0.76; 1.51		---1.37
1.02; 1.85		1.68
0.50; 5.65		1.22
0.84; 1.77		1.07
0.76; 1.53		1.14
0.92; 1.39		1.26
0.77; 2.05		0.88
0.75; 1.02
baricitinib0.72
0.54; 0.97		0.78
0.52; 1.16		0.73
0.54; 0.98		---1.22
0.36; 4.18		0.89
0.58; 1.36		0.78
0.52; 1.17		0.83
0.62; 1.10		0.92
0.54; 1.55		0.64
0.50; 0.82
tofacitinib0.59
0.18; 1.99		0.64
0.18; 2.21		0.60
0.18; 2.00		0.82
0.24; 2.80		---0.73
0.21; 2.54		0.64
0.18; 2.22		0.68
0.20; 2.27		0.75
0.21; 2.72		0.52
0.16; 1.74
casirivimab/imdevimab (Ronapreve)0.82
0.56; 1.19		0.88
0.55; 1.39		0.82
0.56; 1.19		1.13
0.74; 1.72		1.38
0.39; 4.81		---0.88
0.55; 1.40		0.93
0.64; 1.35		1.03
0.58; 1.84		0.72
0.51; 1.01
interferon0.93
0.65; 1.32		1.00
0.64; 1.55		0.93
0.65; 1.32		1.28
0.85; 1.92		1.56
0.45; 5.42		1.14
0.71; 1.81		---1.06
0.75; 1.49		1.17
0.67; 2.06		0.82
0.60; 1.12
tocilizumab 0.88
0.72; 1.07		0.94
0.67; 1.32		0.88
0.72; 1.08		1.21
0.91; 1.61		1.48
0.44; 4.96		1.07
0.74; 1.55		0.95
0.67; 1.34		---1.11
0.69; 1.80		0.77
0.67; 0.89
sarilumab0.79
0.49; 1.28		0.85
0.49; 1.48		0.79
0.49; 1.29		1.09
0.64; 1.85		1.33
0.37; 4.83		0.97
0.54; 1.72		0.85
0.49; 1.49		0.90
0.56; 1.46		---0.70
0.44; 1.11
control1.13
0.97; 1.32		1.22
0.90; 1.66		1.14
0.98; 1.33		1.56
1.21; 2.01		1.91
0.57; 6.36		1.39
0.99; 1.96		1.22
0.89; 1.68		1.29
1.13; 1.48		1.43
0.90; 2.28		---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons